重组人粒细胞集落刺激因子对乳腺癌化疗后骨髓抑制疗效分析.docVIP

重组人粒细胞集落刺激因子对乳腺癌化疗后骨髓抑制疗效分析 　　[摘要] 目的 该文旨在研究探讨应用重组人粒细胞集落刺激因子（recombinant human granulocyte colony-stimulating factor，rhG-CSF）对乳腺癌患者化疗后骨髓抑制的治疗效果。方法 采用回顾性研究，方便选出2013年5月―2016年5月在某医院使用多西他赛（docetaxel）75 mg/m2、环磷酰胺（cyclophosphamide）500 mg/m2化疗方案的100例浸润性乳腺癌患者，在化疗第1个周期结束后1～2 d内皮下注射rhG-CSF为治疗组，化疗后1～2 d内未皮下注射rhG-CSF为对照组，评估两组化疗后骨髓抑制的程度。结果 在应用rhG-CSF的50例患者中，白细胞减少症的发生率为24%，中性粒细胞减少症发生率为20%；在对照组50例患者中，二者发生率分别为80%和70%，差异有统计学意义（P0.05），两组化疗前中性粒细胞计数差异无统计学意义（P=0.1040.05）；化疗后两组白细胞和中性粒细胞计数差异有统计学意义（P0.01）。 ??论 浸润性乳腺癌患者在第一周期化疗后1～2 d内给予rhG-CSF，能减少白细胞降低比率，使骨髓抑制得以减轻，确保化疗顺利进行。 　　[关键词] 重组人粒细胞集落刺激因子；骨髓抑制；疗效分析 　　[中图分类号] R737.9 [文献标识码] A [文章编号] 1674-0742（2017）01（a）-0017-03 　　[Abstract] Objective The purpose of this study was to investigate the effect of recombinant human granulocyte colony-stimulating factor（rhG-CSF）for myelosuppression in patients with breast cancer after chemotherapy. Methods Using retrospective study，Convenient selected 100 cases of invasive breast cancer patients，who use docetaxel 75mg/m2 and cyclophosphamide 500 mg/m2 chemotherapy in the hospital，between May 2013 and May 2016. After first cycles of chemotherapy ， within one or two days， the patients were injected rhG-CSF as the treatment group ，on the contrary ，the patient weren’t injected rhG-CSF as the control group. To evaluate the degree of myelosuppression after chemotherapy. Results The rate of leucopenia was 24% and the rate of neutropenia was 20% in the treatment group，The occurrence rate of the two index was 80% and70% respectively in the control group. There was statistical significance between the two groups（P0.05） and the control group before chemotherapy（P=0.1040.05）. After chemotherapy， the count of white blood cell and neutrophil of the two group was statistical significance（P0.01）. Conclusion The application of rhG-CSF in invasive breast cancer patients after first cycles of chemotherapy can reduce the incidence of white blood cell count， reduce the extent and duration of myelosuppression， and ensure the